Document and Entity Information |
Mar. 29, 2026 |
|---|---|
| Cover [Abstract] | |
| Amendment Flag | true |
| Entity Central Index Key | 0001835022 |
| Document Type | 8-K/A |
| Document Period End Date | Mar. 29, 2026 |
| Entity Registrant Name | Coya Therapeutics, Inc. |
| Entity Incorporation State Country Code | DE |
| Entity File Number | 001-41583 |
| Entity Tax Identification Number | 85-4017781 |
| Entity Address, Address Line One | 5850 San Felipe St. |
| Entity Address, Address Line Two | Suite 500 |
| Entity Address, City or Town | Houston |
| Entity Address, State or Province | TX |
| Entity Address, Postal Zip Code | 77057 |
| City Area Code | (800) |
| Local Phone Number | 587-8170 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Common Stock, par value $0.0001 per share |
| Trading Symbol | COYA |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | true |
| Entity Ex Transition Period | false |
| Amendment Description | This Amendment No. 1 to Current Report on Form 8-K/A (the “Amendment”) amends the Current Report on Form 8-K of Coya Therapeutics, Inc. (the “Company”) dated March 29, 2026 and filed with the Securities and Exchange Commission on April 2, 2026 (the “Original Form 8-K”), which disclosed the appointment of Mark H. Pavao to the Board of Directors of the Company (the “Board”), effective April 1, 2026. At the time of filing the Original Form 8-K, no determination had been made with respect to the appointment of Mr. Pavao to any committees of the Board. |